AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38035176 — intervention group
Group type: EXPERIMENTAL
Intervention: Enroll-HD observational study
Number of subjects: 15982
Study 38035176 — intervention group
Group type: EXPERIMENTAL
Intervention: Core assessments at annual visits
Number of subjects: 15982
Study 38035176 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDPA (Enroll-HD Phenotype Atlas)
Number of subjects: 15982
Study 38035207 — intervention group
Group type: EXPERIMENTAL
Intervention: Half Fourier Single-Shot Turbo Spin-Echo (HASTE) sequence
Number of subjects: 5
Study 38035207 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Balanced Steady-State Free Precession (bSSFP) sequence
Number of subjects: 5
Study 38035207 — intervention group
Group type: EXPERIMENTAL
Intervention: HASTE sequence in key cardiac planes
Number of subjects: 5
Study 38035207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac conduction system contours
Number of subjects: 5
Study 38035216 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR group (pneumatic cuff at 80% limb occlusion pressure)
Number of subjects: 46
Study 38035216 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 38035216 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR group
Number of subjects: 46
Study 38035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian version of the Elderly Mobility Scale (I-EMS)
Number of subjects: 10
Study 38035363 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g specific collagen peptides (SCP)
Number of subjects: 55
Study 38035363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 55
Study 38035641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) reduction
Number of subjects: 1895
Study 38035641 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial glucose (PPG) reduction
Number of subjects: 1895
Study 38035641 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG and PPG reductions
Number of subjects: 1895
Study 38035655 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC group
Number of subjects: 100
Study 38035655 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 38035725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1954
Study 38035725 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 1954
Study 38035737 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on pramipexole for 9 weeks
Number of subjects: 80
Study 38035737 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label treatment after RCT phase
Number of subjects: 80
Study 38035737 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 9 weeks
Number of subjects: 80
Study 38035747 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (bradykinin inhibitor)
Number of subjects: 0
Study 38035747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38035766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (50-g OGTT)
Number of subjects: 19
Study 38035766 — intervention group
Group type: COMPARATOR
Intervention: Isoglycemic IV glucose infusion (IIGI)
Number of subjects: 19
Study 38035997 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with C15:0 supplementation
Number of subjects: 88
Study 38035997 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet without C15:0 supplementation
Number of subjects: 88
Study 38035997 — intervention group
Group type: COMPARATOR
Intervention: Control (habitual diet and no C15:0 supplementation)
Number of subjects: 88
Study 38036071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 805
Study 38036071 — intervention group
Group type: COMPARATOR
Intervention: Low-fat Diet
Number of subjects: 805
Study 38036071 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Antioxidant Index (DAI) components
Number of subjects: 805
Study 38036166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 137
Study 38036166 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 137
Study 38036220 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (SGLTi)
Number of subjects: 40
Study 38036399 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pelvic movements on a Swiss ball
Number of subjects: 200
Study 38036487 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily
Number of subjects: 547
Study 38036487 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir (dose-adjusted for renal clearance)
Number of subjects: 547
Study 38036487 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 547
Study 38036487 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 547
Study 38036712 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat 8 mg PO days 1 and 15 + Pembrolizumab 200 mg IV day 1 every 21 days
Number of subjects: 28
Study 38036720 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa monotherapy 2.5-15 mg/kg on Day 1 or Days 1/8 of a 21-day cycle
Number of subjects: 153
Study 38036720 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa monotherapy or combination therapy with oral venetoclax 400-800 mg daily (1.25-7.5 mg/kg Days 1/8/15 of a 21-day cycle)
Number of subjects: 153
Study 38036720 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa (3.75 or 7.5 mg/kg Days 1/8/15/22 of a 28-day cycle) and FOLFIRI regimen with/without bevacizumab
Number of subjects: 153
Study 38036761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve Bif195 (≥10 billion CFU) co-administered with aspirin 300 mg daily for 4 weeks
Number of subjects: 25
Study 38036761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 38036930 — intervention group
Group type: EXPERIMENTAL
Intervention: Von Willebrand factor (VWF) concentrates-pure or in association with Factor VIII (FVIII)
Number of subjects: 988
Study 38036930 — intervention group
Group type: COMPARATOR
Intervention: Highly purified VWF or VWF combined with FVIII
Number of subjects: 988
Study 38036930 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF concentrates
Number of subjects: 988
Study 38036946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg IV at Week 0, 90 mg SC at Week 8)
Number of subjects: 323
Study 38037105 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard of care
Number of subjects: 0
Study 38037105 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 0
Study 38037105 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth using cellular-enabled electronic dose monitoring
Number of subjects: 0
Study 38037105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mHealth and psychosocial support
Number of subjects: 0
Study 38037105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38037108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of CBD
Number of subjects: 120
Study 38037108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 38037119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline, linezolid, clofazimine, and delamanid (experimental arm)
Number of subjects: 324
Study 38037119 — intervention group
Group type: COMPARATOR
Intervention: WHO standard of care for pre-XDR TB (control arm)
Number of subjects: 324
Study 38037188 — intervention group
Group type: EXPERIMENTAL
Intervention: hp-HMG (225 IU/day)
Number of subjects: 112
Study 38037188 — intervention group
Group type: COMPARATOR
Intervention: r-FSH (225 IU/day)
Number of subjects: 112
Study 38037749 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy lifestyle intervention
Number of subjects: 40
Study 38037804 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB)
Number of subjects: 165
Study 38037804 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 165
Study 38037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and dietary interventions
Number of subjects: 0
Study 38037817 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38037839 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-10352 at 6 mg QD
Number of subjects: 18
Study 38037839 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-10352 at 8 mg QD
Number of subjects: 18
Study 38037839 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-10352 (all doses)
Number of subjects: 18
Study 38038169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of inactivity
Number of subjects: 184
Study 38038169 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active older adults
Number of subjects: 184
Study 38038169 — intervention group
Group type: COMPARATOR
Intervention: Higher levels of inactivity
Number of subjects: 184
Study 38038169 — intervention group
Group type: COMPARATOR
Intervention: Physically inactive participants
Number of subjects: 184
Study 38038339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density-lipoprotein cholesterol (LDL-c) levels modeled as a continuous variable
Number of subjects: 12334
Study 38038339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-c levels
Number of subjects: 12334
Study 38038395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (at least 4 sessions of 16 hours)
Number of subjects: 170
Study 38038395 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 170
Study 38038395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 170
Study 38038620 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation
Number of subjects: 232
Study 38038620 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 232
Study 38038626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Number of subjects: 3013
Study 38038829 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning autosegmentation models for tumor segmentation
Number of subjects: 259
Study 38038866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV vaccine booster dose
Number of subjects: 89
Study 38039007 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-based conversational AI application
Number of subjects: 32
Study 38039007 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 32
Study 38039341 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month meditation training
Number of subjects: 137
Study 38039341 — intervention group
Group type: COMPARATOR
Intervention: English language training
Number of subjects: 137
Study 38039341 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 137
Study 38039357 — intervention group
Group type: EXPERIMENTAL
Intervention: EpCAM-CAR-T cells
Number of subjects: 12
Study 38039427 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (200 mg subcutaneously once every 3 weeks)
Number of subjects: 643
Study 38039427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 38039427 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab plus pembrolizumab and chemotherapy
Number of subjects: 643
Study 38039427 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab and chemotherapy
Number of subjects: 643
Study 38039429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 29
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: HRD-S in non-TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: HRD-S in TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: HRD-W in non-TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: HRD-W in TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-S non-TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-S TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-W non-TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-W TNBC
Number of subjects: 201
Study 38039432 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-like PAM50 signature in HRD-S non-TNBC
Number of subjects: 201
Study 38039511 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-mediated TTP (iTTP)
Number of subjects: 108
Study 38039511 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired TTP of unidentified mechanism (uTTP)
Number of subjects: 108
Study 38039511 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital TTP (cTTP)
Number of subjects: 108
Study 38039831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 0
Study 38039991 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg intravenously once every 4 weeks) with chemoradiotherapy
Number of subjects: 770
Study 38039991 — intervention group
Group type: COMPARATOR
Intervention: Placebo with chemoradiotherapy
Number of subjects: 770
Study 38039991 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 770
Study 38039991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study 38039992 — intervention group
Group type: EXPERIMENTAL
Intervention: avasopasem (90 mg)
Number of subjects: 42
Study 38039992 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 38039992 — intervention group
Group type: EXPERIMENTAL
Intervention: avasopasem
Number of subjects: 42
Study 38039993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 794
Study 38039993 — intervention group
Group type: COMPARATOR
Intervention: Lenvatinib plus placebo
Number of subjects: 794
Study 38040019 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of gluten intake
Number of subjects: 84
Study 38040019 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual gluten intake
Number of subjects: 84
Study 38040019 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 84
Study 38040274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod
Number of subjects: 1619
Study 38040277 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy
Number of subjects: 65
Study 38040277 — intervention group
Group type: COMPARATOR
Intervention: Oral cinacalcet
Number of subjects: 65
Study 38040423 — intervention group
Group type: EXPERIMENTAL
Intervention: Living donor kidney transplantation information delivery
Number of subjects: 20
Study 38040423 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation counselling approach
Number of subjects: 20
Study 38040452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital risk stratification and direct transfer to a PCI centre based on the preHEART score
Number of subjects: 1069
Study 38040478 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily or event-based oral PrEP (tenofovir disoproxil maleate with emtricitabine)
Number of subjects: 21356
Study 38040478 — intervention group
Group type: COMPARATOR
Intervention: Non-trial attendees (control group)
Number of subjects: 21356
Study 38040478 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participants (MSM)
Number of subjects: 21356
Study 38040875 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid therapy (ACS)
Number of subjects: 408
Study 38040987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestasis patients
Number of subjects: 17
Study 38040987 — intervention group
Group type: COMPARATOR
Intervention: Controls without cholestasis
Number of subjects: 17
Study 38041042 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + PEERC
Number of subjects: 54
Study 38041042 — intervention group
Group type: COMPARATOR
Intervention: PT
Number of subjects: 54
Study 38041058 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing and ART initiation/adherence among men and women with AHD
Number of subjects: 64
Study 38041058 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV care decision-making
Number of subjects: 64
Study 38041058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-tailored counseling services and community messaging
Number of subjects: 64
Study 38041077 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 75
Study 38041077 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjuvant chemotherapy
Number of subjects: 75
Study 38041077 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 38041148 — intervention group
Group type: EXPERIMENTAL
Intervention: online cognitive behavioural therapy intervention based on the unified protocol
Number of subjects: 214
Study 38041148 — intervention group
Group type: COMPARATOR
Intervention: online progressive muscle relaxation training
Number of subjects: 214
Study 38041148 — intervention group
Group type: COMPARATOR
Intervention: waiting-list control group
Number of subjects: 214
Study 38041177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia (natremia <135 mmol/L)
Number of subjects: 1163
Study 38041177 — intervention group
Group type: COMPARATOR
Intervention: Normal natremia (135-145 mmol/L)
Number of subjects: 1163
Study 38041177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypernatremia (natremia >145 mmol/L)
Number of subjects: 1163
Study 38041180 — intervention group
Group type: EXPERIMENTAL
Intervention: m-health self-managed exercise program plus health education
Number of subjects: 0
Study 38041180 — intervention group
Group type: COMPARATOR
Intervention: Health education alone
Number of subjects: 0
Study 38041762 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID syndrome (PCS) patients
Number of subjects: 0
Study 38041762 — intervention group
Group type: COMPARATOR
Intervention: Fully SARS-CoV-2-infection-recovered (CR) participants
Number of subjects: 0
Study 38041762 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2-infection-naïve (CN) participants
Number of subjects: 0
Study 38041959 — intervention group
Group type: EXPERIMENTAL
Intervention: STIM (spatial-temporal integration model)
Number of subjects: 169
Study 38041959 — intervention group
Group type: EXPERIMENTAL
Intervention: STIM
Number of subjects: 169
Study 38042152 — intervention group
Group type: EXPERIMENTAL
Intervention: Three short-term infections with 50 infectious Necator americanus third-stage filariform larvae (50L3)
Number of subjects: 23
Study 38042152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 38042167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 12011
Study 38042207 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic powered resection (EPR) device
Number of subjects: 65
Study 38042412 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g GOS/FOS + iron
Number of subjects: 191
Study 38042412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g GOS/FOS + iron
Number of subjects: 191
Study 38042412 — intervention group
Group type: COMPARATOR
Intervention: No prebiotics (iron group)
Number of subjects: 191
Study 38042459 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-PATHFAST 0/1h-algorithm
Number of subjects: 1532
Study 38042459 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-PATHFAST 0/2h-algorithm
Number of subjects: 1532
Study 38042525 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus platinum-pemetrexed (combination)
Number of subjects: 557
Study 38042525 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib monotherapy
Number of subjects: 557
Study 38042773 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot for medication management
Number of subjects: 110
Study 38042773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no robot)
Number of subjects: 110
Study 38042801 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR 300-mg maintenance dose
Number of subjects: 0
Study 38042801 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR 100-mg maintenance dose
Number of subjects: 0
Study 38042801 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR 100-mg and 300-mg maintenance doses
Number of subjects: 0
Study 38042811 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurements of SpO2
Number of subjects: 40
Study 38042811 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily respiratory exercises
Number of subjects: 40
Study 38042811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 40
Study 38042811 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up termination
Number of subjects: 40
Study 38042851 — intervention group
Group type: EXPERIMENTAL
Intervention: Olipudase alfa treatment for 2 years
Number of subjects: 36
Study 38042851 — intervention group
Group type: COMPARATOR
Intervention: Cross-over group after 1 year of olipudase alfa treatment
Number of subjects: 36
Study 38043045 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-embedded alert
Number of subjects: 2211
Study 38043045 — intervention group
Group type: EXPERIMENTAL
Intervention: Message
Number of subjects: 2211
Study 38043045 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2211
Study 38043045 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert
Number of subjects: 2211
Study 38043556 — intervention group
Group type: EXPERIMENTAL
Intervention: ansuvimab
Number of subjects: 787
Study 38043556 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN-EB3
Number of subjects: 787
Study 38043556 — intervention group
Group type: EXPERIMENTAL
Intervention: remdesivir
Number of subjects: 787
Study 38043556 — intervention group
Group type: EXPERIMENTAL
Intervention: ZMapp
Number of subjects: 787
Study 38043558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium-177
Number of subjects: 200
Study 38043558 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 200
Study 38043867 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime home parenteral nutrition (HPN)
Number of subjects: 20
Study 38043867 — intervention group
Group type: COMPARATOR
Intervention: Overnight home parenteral nutrition (HPN)
Number of subjects: 20